Economic Observation Network China Biopharmaceutical (01177) has recently benefited from the release of support policies for pharmaceutical innovation. Its self-developed innovative drugs have been selected as heavyweight abstracts for international academic conferences, and the expected valuation recovery of the sector has increased.

Policy situation:
On October 13-14, the National Healthcare Security Administration and the State owned Assets Supervision and Administration Commission successively released signals supporting pharmaceutical innovation. The Healthcare Security Administration proposed to explore the "pre approval system for medical service prices", aiming to shorten the admission cycle of innovative drugs and equipment from approval to clinical application This directly benefits the commercialization expectations of innovative pharmaceutical companies.

Business status of the company:
On October 14th, the company announced that its self-developed innovative drug TQ-A3334 (TLR7 agonist) has been selected for the latest breakthrough abstract (LBA) at the 2026 AASLD Annual Meeting. The results will be announced orally in collaboration with GSK's product Bepirovessen (ASO) With the ESMO annual meeting approaching in late October, sentiment in the sector is heating up - JPMorgan Chase pointed out that multiple Chinese pharmaceutical companies will experience intensive catalysis at ESMO, which is expected to drive sector valuation repair 。

The above content is based on publicly available information and does not constitute investment advice.